Repertoire Immune Medicines has collaborated with Eli Lilly for the development of tolerising therapies to treat several ...
The US Food and Drug Administration (FDA) will start accepting applications for the new PreCheck scheme that will streamline ...
AstraZeneca has returned to CSPC with a licensing deal for the Chinese company’s monthly injectables for obesity.
IQVIA has announced a strategic, long-term partnership with Boehringer Ingelheim focused on strengthening data capabilities across therapeutic areas.
Sanofi's sales grew 9.9% YoY – driven by a diverse range of portfolio classics and new launches across immunology, oncology and rare disease.
Roche’s adjusted operating profit rose by a lower-than-expected 5% in 2025, due to the weakened US dollar, despite the ...
The two companies reportedly could not agree on a price, leaving pharma’s first potential megadeal of 2026 on ice.
Speaking at the World Economic Forum in Davos, Donald Trump said tariffs helped fix the long-time drug pricing scam in the US ...
This year, sales of Eliquis (apixaban) are projected to decline by 15.2% due to the loss of its European market exclusivity ...
Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss. In a move that ...
The US Food and Drug Administration (FDA) has accepted for priority review Otsuka Pharmaceutical’s new drug application (NDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results